Transparency in Decision Modelling: What, Why, Who and How?

[1]  Renée J. Goldberg Arnold,et al.  From Machine Learning in Drug Discovery to Pharmacoeconomics , 2020 .

[2]  Devin Incerti,et al.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis , 2019, PharmacoEconomics.

[3]  G. Frederix.  Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations , 2019, PharmacoEconomics - open.

[4]  D. Sin,et al.  Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada , 2018, bioRxiv.

[5]  S. Goodman,et al.  Statistical Code to Support the Scientific Story , 2018, Annals of Internal Medicine.

[6]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  Sean Ekins,et al.  Ahead of Our Time: Collaboration in Modeling Then and Now , 2017, PharmacoEconomics.

[8]  Casey S Greene,et al.  Data-Sharing Models , 2017, The New England journal of medicine.

[9]  A. Hatswell,et al.  Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling , 2017, PharmacoEconomics.

[10]  Christopher James Sampson,et al.  Model Registration: A Call to Action , 2017, PharmacoEconomics - Open.

[11]  Sean Khozin,et al.  Advantages of a Truly Open-Access Data-Sharing Model. , 2017, The New England journal of medicine.

[12]  Reiner Leidl,et al.  External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  S. Bryan,et al.  Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  Fernando Alarid-Escudero,et al.  An Overview of R in Health Decision Sciences , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  R. Akehurst,et al.  Benefits, Challenges and Potential Strategies of Open Source Health Economic Models , 2016, PharmacoEconomics.

[16]  E. Miguel,et al.  Transparency, Reproducibility, and the Credibility of Economics Research , 2016, Journal of Economic Literature.

[17]  W. Herman,et al.  How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review , 2016, PharmacoEconomics.

[18]  P. Vemer,et al.  AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users , 2015, PharmacoEconomics.

[19]  T. Feenstra,et al.  The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling , 2015, Applied Health Economics and Health Policy.

[20]  F. Fagnani,et al.  Economic evaluation in chronic pain: a systematic review and de novo flexible economic model , 2015, The European Journal of Health Economics.

[21]  Peter Tanuseputro,et al.  The Population Health Model (POHEM): an overview of rationale, methods and applications , 2015, Population Health Metrics.

[22]  Julie Ratcliffe,et al.  Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake , 2015, Applied Health Economics and Health Policy.

[23]  Emma Frew,et al.  Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis , 2015, PharmacoEconomics.

[24]  Gerardus W. J. Frederix,et al.  Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions , 2015, PharmacoEconomics.

[25]  M. Woodward,et al.  A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation , 2014, Heart.

[26]  C. Mitton,et al.  Breaking the addiction to technology adoption. , 2014, Health economics.

[27]  R. R. Holman,et al.  UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 , 2013, Diabetologia.

[28]  John Hornberger,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[29]  Jonathan Karnon,et al.  Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[31]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, BMJ.

[32]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  Uwe Siebert,et al.  Modeling Good Research Practices—Overview , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[35]  James D. Herbsleb,et al.  Social coding in GitHub: transparency and collaboration in an open software repository , 2012, CSCW.

[36]  Bradley M. Hemminger,et al.  Decoupling the scholarly journal , 2011, Front. Comput. Neurosci..

[37]  Jonathan Karnon,et al.  Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions , 2011, PharmacoEconomics.

[38]  P. Barton.  Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans. , 2011, Rheumatology.

[39]  M. Weinstein,et al.  Assessing the Performance of a Computer-Based Policy Model of HIV and AIDS , 2010, PloS one.

[40]  Finn Børlum Kristensen,et al.  The HTA Core Model: A novel method for producing and reporting health technology assessments , 2009, International Journal of Technology Assessment in Health Care.

[41]  M. Drummond,et al.  Use of pharmacoeconomics in drug reimbursement in Australia, Canada and the UK: what can we learn from international experience? , 2009 .

[42]  A E Ades,et al.  Use of evidence in economic decision models: practical issues and methodological challenges. , 2007, Health economics.

[43]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[44]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[45]  S. Goodman,et al.  Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.

[46]  R. Goeree,et al.  Building Bridges Between Academic Research and Policy Formulation , 2006, PharmacoEconomics.

[47]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[48]  D. MacLean.  Setting Limits Fairly: Can We Learn to Share Medical Resources? , 2003 .

[49]  S. Goodacre,et al.  Being economical with the truth: how to make your idea appear cost effective , 2002, Emergency medicine journal : EMJ.

[50]  Norman Daniels,et al.  Setting Limits Fairly: Can We Learn to Share Medical Resources? , 2002 .

[51]  N. Daniels,et al.  Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. , 1997, Philosophy & public affairs.

[52]  J. Mason,et al.  Publication Bias in Clinical Trials and Economic Analyses , 1997, PharmacoEconomics.

[53]  J. Sacristán,et al.  Publication bias in health economic studies. , 1997, PharmacoEconomics.

[54]  A. Towse,et al.  Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation , 2018 .

[55]  Sean Khozin,et al.  Data-Sharing Models. , 2017, New England Journal of Medicine.

[56]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[57]  Sean Ekins,et al.  Time for Cooperation in Health Economics among the Modelling Community , 2012, PharmacoEconomics.

[58]  Ping Zhang,et al.  Guidelines for computer modeling of diabetes and its complications , 2004 .

[59]  Y. Hamamoto,et al.  Guidelines for computer modeling of diabetes and its complications. , 2004, Diabetes care.